BRM Immunotherapy of Orthotopically Implanted Murine Bladder Tumours: Treatment Response by Monitoring MRI
The authors evaluated magnetic resonance imaging (MRI) for monitoring orthotopic bladder tumour growth and treatment response to intravesical immunotherapy with the biological response modifiers (BRMs): recombinant tumour necrosis factor alpha (TNF-α), combination of TNF-α plus interferon gamma (IFN...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1992-01-01
|
| Series: | Canadian Journal of Infectious Diseases |
| Online Access: | http://dx.doi.org/10.1155/1992/510914 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The authors evaluated magnetic resonance imaging (MRI) for monitoring orthotopic bladder tumour
growth and treatment response to intravesical immunotherapy with the biological response modifiers
(BRMs): recombinant tumour necrosis factor alpha (TNF-α), combination of TNF-α plus interferon gamma
(IFN-γ) and interleukin-2 (IL-2). MRI demonstrated detection of early superficial murine bladder tumour
(MBT-2) and accurate sequential assessment of the topography and depth of intravesical tumour involvement.
Response to intravesical instillations with multiple doses ofBRMs was assessed against early stage
MBT-2 bladder tumours (confirmed by MRI) 14 days after transurethral tumour implantation. Serial MRI
scans of TNF-α treated mice revealed significant retardation of tumour growth which correlated well with
corresponding histological examination of the whole mount bladder sections illustrating areas and depth
of tumour regression. Intravesical instillation of combination TNF-α plus IFN-γ into tumour-bearing mice
caused tumour growth inhibition up to 21 days following treatment; the results, however, were not superior
to those noted with TNF-α alone. Sequential MR images of tumour-bearing bladders following intravesical
treatment with IL-2 revealed tumour regression with no visible tumour from day 21 to 33 post tumour
implant. Histological examination revealed foci of carcinoma in situ only. Control untreated bladders
revealed deeply invasive transitional cell carcinoma. These results show that MRI offers a dependable tool
for noninvasive monitoring of tumour growth and of the course of experimental bladder tumour during
therapy. |
|---|---|
| ISSN: | 1180-2332 |